---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-25-000013"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2025-02-24T23:59:59+00:00"
generated_at: "2026-05-26T06:24:09.589886+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma approves 1-for-72 reverse stock split to maintain NYSE American listing

## Summary
- Reverse split ratio of 1-for-72; effective 12:01 AM ET on February 26, 2025.
- Outstanding shares reduced from ~79.9 million to ~1.1 million; fractional shares rounded up.
- Authorized shares increased from 500 million to 1.04 billion at special meeting.
- Ticker 'AEON' unchanged; new CUSIP 00791X 209; votes: 32.6M for, 3.6M against.
- Purpose: increase share price to comply with NYSE American continued listing standards.

## SEC filing metadata
- accession: 0001837607-25-000013
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2025-02-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.03, 5.03, 5.07, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000013/0001837607-25-000013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000013/aeon-20250224x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-25-000013
- JSON: https://secwatch.observer/filing/0001837607-25-000013.json
- Plain text: https://secwatch.observer/filing/0001837607-25-000013.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.